Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why

Earlier this month, the company announced upbeat data from a preclinical study evaluating certepetide for treating intrahepatic cholangiocarcinoma, an aggressive form of cancer, with a poor prognosis. Certepetide is an investigational drug candidate that allows co-administered or tethered anti-cancer drugs to better penetrate solid tumors by activating a novel uptake pathway. The candidate has exhibited the potential to improve the tumor environment, thereby making tumors more responsive to immunotherapy. T ...